MX2017011434A - Compuestos heterociclicos triciclicos sustituidos. - Google Patents
Compuestos heterociclicos triciclicos sustituidos.Info
- Publication number
- MX2017011434A MX2017011434A MX2017011434A MX2017011434A MX2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compounds
- compounds
- tricyclic heterocyclic
- substituted tricyclic
- cr3r3
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
Se describen los compuestos de la Fórmula (I) o una sal de los mismos, en donde: X es N; W es: (i) -(CR3R3)1-4-; (ii) -(CR3R3)x-Y-(CR3R3)y-; o (iii) -Y-(CR3R3)2-Y-; e Y, R1, R2, R3, R5, R6, R8, x, e y son definidos en la presente. También se describen los métodos de uso de tales compuestos como moduladores de TNFa, y las composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de trastornos inflamatorios y autoinmunitarios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134769P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022737 WO2016149436A1 (en) | 2015-03-18 | 2016-03-17 | Substituted tricyclic heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011434A true MX2017011434A (es) | 2018-01-25 |
Family
ID=55640932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011434A MX2017011434A (es) | 2015-03-18 | 2016-03-17 | Compuestos heterociclicos triciclicos sustituidos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10189840B2 (es) |
| EP (1) | EP3271360B1 (es) |
| JP (1) | JP6793657B2 (es) |
| KR (1) | KR102654709B1 (es) |
| CN (1) | CN107635993B (es) |
| AU (1) | AU2016233288A1 (es) |
| BR (1) | BR112017019773A2 (es) |
| CA (1) | CA2980159A1 (es) |
| EA (1) | EA032315B1 (es) |
| ES (1) | ES2797805T3 (es) |
| IL (1) | IL254424A0 (es) |
| MX (1) | MX2017011434A (es) |
| SG (1) | SG11201707469WA (es) |
| WO (1) | WO2016149436A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6793658B2 (ja) | 2015-03-18 | 2020-12-02 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
| WO2016149439A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of tnf |
| WO2016168641A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| CA2994703A1 (en) | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| WO2018167176A1 (en) | 2017-03-15 | 2018-09-20 | Ucb Biopharma Sprl | Fused pentacyclic imidazole derivatives as modulators of tnf activity |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6038397B2 (ja) * | 1980-03-06 | 1985-08-31 | エスエス製薬株式会社 | チアジノイミダゾ−ル誘導体及びその製造法 |
| DE69814049T2 (de) | 1997-02-25 | 2004-02-19 | The Government of the United States of America, as represented by the Secretary National Institute of Health, Office of Technology Transfer | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| JP2003512467A (ja) * | 1999-10-27 | 2003-04-02 | ノバルティス アクチエンゲゼルシャフト | チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途 |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| CN1633434A (zh) | 2002-01-31 | 2005-06-29 | 第一制药株式会社 | 咪唑并[1,2－a]吡啶衍生物 |
| AU2003298839A1 (en) | 2002-12-03 | 2004-06-23 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| ATE538120T1 (de) * | 2007-06-26 | 2012-01-15 | Sanofi Sa | Regioselektive, metallkatalysierte synthese annelierter benzimidazole und azabenzimidazole |
| FR2919610B1 (fr) * | 2007-08-02 | 2009-10-16 | Sanofi Aventis Sa | Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique |
| WO2009045174A1 (en) | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| SG171815A1 (en) * | 2008-12-19 | 2011-07-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| CA2756137C (en) | 2009-03-23 | 2015-11-24 | Siemens Medical Solutions Usa, Inc. | Imaging agents for detecting neurological disorders |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| BR112014030940B1 (pt) * | 2012-06-11 | 2022-09-06 | UCB Biopharma SRL | Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos |
| ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US9920052B2 (en) | 2013-12-09 | 2018-03-20 | Ucb Biopharma Sprl | Imidazopyridine derivatives as modulators of TNF activity |
| GB201321745D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6483697B2 (ja) | 2013-12-09 | 2019-03-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体 |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2980464T3 (es) | 2014-10-06 | 2024-10-01 | Signal Pharm Llc | Productos intermedios sintéticos útiles para preparar compuestos de aminopurina sustituidos |
| WO2016149439A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Heterocyclic compounds useful as inhibitors of tnf |
| JP6793658B2 (ja) | 2015-03-18 | 2020-12-02 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｎｆ阻害剤として有用な三環式ヘテロ環式化合物 |
-
2016
- 2016-03-17 US US15/558,692 patent/US10189840B2/en active Active
- 2016-03-17 KR KR1020177029449A patent/KR102654709B1/ko active Active
- 2016-03-17 MX MX2017011434A patent/MX2017011434A/es unknown
- 2016-03-17 EA EA201792034A patent/EA032315B1/ru not_active IP Right Cessation
- 2016-03-17 SG SG11201707469WA patent/SG11201707469WA/en unknown
- 2016-03-17 CN CN201680026733.XA patent/CN107635993B/zh active Active
- 2016-03-17 ES ES16712645T patent/ES2797805T3/es active Active
- 2016-03-17 JP JP2017549092A patent/JP6793657B2/ja active Active
- 2016-03-17 AU AU2016233288A patent/AU2016233288A1/en not_active Abandoned
- 2016-03-17 WO PCT/US2016/022737 patent/WO2016149436A1/en not_active Ceased
- 2016-03-17 BR BR112017019773-1A patent/BR112017019773A2/pt not_active Application Discontinuation
- 2016-03-17 CA CA2980159A patent/CA2980159A1/en not_active Abandoned
- 2016-03-17 EP EP16712645.7A patent/EP3271360B1/en active Active
-
2017
- 2017-09-11 IL IL254424A patent/IL254424A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2980159A1 (en) | 2016-09-22 |
| KR102654709B1 (ko) | 2024-04-03 |
| US10189840B2 (en) | 2019-01-29 |
| EA201792034A1 (ru) | 2018-03-30 |
| CN107635993A (zh) | 2018-01-26 |
| KR20170129810A (ko) | 2017-11-27 |
| ES2797805T3 (es) | 2020-12-03 |
| EA032315B1 (ru) | 2019-05-31 |
| SG11201707469WA (en) | 2017-10-30 |
| EP3271360A1 (en) | 2018-01-24 |
| US20180111936A1 (en) | 2018-04-26 |
| BR112017019773A2 (pt) | 2018-05-15 |
| IL254424A0 (en) | 2017-11-30 |
| CN107635993B (zh) | 2020-05-22 |
| JP2018508553A (ja) | 2018-03-29 |
| WO2016149436A1 (en) | 2016-09-22 |
| AU2016233288A1 (en) | 2017-11-09 |
| JP6793657B2 (ja) | 2020-12-02 |
| EP3271360B1 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011434A (es) | Compuestos heterociclicos triciclicos sustituidos. | |
| HK1252623A1 (zh) | 可用作TNFα调节剂的杂环化合物 | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| EA202091483A1 (ru) | Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr | |
| MX2017011433A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf). | |
| EA202091484A1 (ru) | 4-азаиндольные соединения | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| EA201992674A1 (ru) | Тиенопиридины и бензотиофены в качестве ингибиторов irak4 | |
| EA201990169A1 (ru) | Диметоксифенилзамещенные соединения индола в качестве ингибиторов tlr7, tlr8 или tlr9 | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| MX2017011577A (es) | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). | |
| PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| MX374729B (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| EA201791293A1 (ru) | Сайт-специфическое дозирование ингибитора btk | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| MX378963B (es) | Compuestos de naftiridina como inhibidores de quinasa jak. | |
| EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| EA201991029A1 (ru) | Ингибиторы magl | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| MX2018001173A (es) | Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. |